Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy
| العنوان: | Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy |
|---|---|
| المؤلفون: | Johan Hansson, Ulrik Ringborg, Suzanne Egyhazi, Shuhua Ma |
| المصدر: | Oncology Reports. |
| بيانات النشر: | Spandidos Publications, 2002. |
| سنة النشر: | 2002 |
| مصطلحات موضوعية: | Adult, Male, congenital, hereditary, and neonatal diseases and abnormalities, Cancer Research, Pathology, medicine.medical_specialty, Methyltransferase, DNA Repair, Base Pair Mismatch, DNA repair, Dacarbazine, medicine.medical_treatment, Antineoplastic Agents, Biology, O(6)-Methylguanine-DNA Methyltransferase, Proto-Oncogene Proteins, medicine, Humans, Neoplasm Metastasis, Melanoma, neoplasms, Adaptor Proteins, Signal Transducing, Aged, Chemotherapy, Nuclear Proteins, Cancer, O-6-methylguanine-DNA methyltransferase, General Medicine, Middle Aged, medicine.disease, Immunohistochemistry, digestive system diseases, Neoplasm Proteins, DNA-Binding Proteins, MutS Homolog 2 Protein, Oncology, Cancer research, Female, DNA mismatch repair, Carrier Proteins, MutL Protein Homolog 1, medicine.drug |
| الوصف: | DNA mismatch repair (MMR) deficiency and increased O6-methylguanine-DNA methyltransferase (MGMT) activity have been related to resistance to O6-guanine methylating agents in tumour cell lines. However, the clinical relevance of MMR and MGMT as drug resistance factors is still unclear. In a retrospective study, the expression levels of the MMR proteins, hMSH2, hMSH6 and hMLH1, were analysed by immunohistochemistry in melanoma metastases from 64 patients, who had received dacarbazine (DTIC) based chemotherapy. More than half of the melanoma patients had tumours with no nuclear staining for either hMSH2 or hMSH6 or both, while all tumours showed positive nuclear staining for hMLH1. The response rates were similar in patients with hMSH2 and/or hMSH6 positive tumours to these in patients with negative tumours. By combination of MMR with previously obtained MGMT data, only 2 of 12 responders had tumours with low MGMT and positive MMR expression. Still all except 3 of the non-responders were identified by having either high MGMT expression or absent staining for hMSH2 or hMSH6 or both in their tumours. However, there was no significant correlation of MMR expression alone or combined with MGMT levels with clinical response to DTIC-based chemotherapy in metastatic melanoma. |
| تدمد: | 1791-2431 1021-335X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::966b6d560cca450ca4ec04729c6fd591Test https://doi.org/10.3892/or.9.5.1015Test |
| رقم الانضمام: | edsair.doi.dedup.....966b6d560cca450ca4ec04729c6fd591 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17912431 1021335X |
|---|